Basic information
- CAS
101-47-3- Standard SMILES
CC(Cc1ccccc1)N(C)Cc1ccccc1- InChIKey
YXKTVDFXDRQTKV-UHFFFAOYSA-N- Molecular formula
- C17H21N
- Average molar mass
- 239.35 g/mol
- Monoisotopic mass
- 239.16739967
Overview
A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)
Names & identifiers
- Preferred name
- Benzfetamine
- IUPAC
- N-benzyl-N-methyl-1-phenylpropan-2-amine
- English name
- D-Benzphetamine
- Molecular formula
- C17H21N
- Molecular weight
- 239.36
Names & synonyms
RefChem:1078733Benzfetamined-Benzphetamine101-47-3N-benzyl-N-methyl-1-phenylpropan-2-aminedl-Benzphetamine(+/-)-benzphetamineBenzphetamine, (+/-)-QZH832I91BBenzfetamine (INN)(+-)-BenzphetaminwUNII-QZH832I91B
Show more names
*Amphetamine Impurity 31Benzphetamine, racemic mixtureN,α-Dimethyl-N-benzylbenzeneethanaminebenzyl-methyl-(1-methyl-2-phenyl-ethyl)amineN-methyl-1-phenyl-N-(phenylmethyl)propan-2-amineBenzeneethanamine, N,α-dimethyl-N-(phenylmethyl)-
Benzphetamine,N,alpha-Dimethyl-N-(phenylmethyl)benzeneethanamineSCHEMBL678807Benzeneethanamine, N,alpha-dimethyl-N-(phenylmethyl)-DTXSID50859308YXKTVDFXDRQTKV-UHFFFAOYSA-NN-Benzyl-N-methyl-1-phenyl-2-propanamine #C07538
Database identifiers
- CAS
101-47-3- PubChem CID
- 2341
- DTXSID
DTXSID50859308- UNII
Properties
Computed structural properties
- XLogP
- 4.1
- Topological polar surface area
- 3.2 Ų
- Hydrogen bond donors
- 0
- Hydrogen bond acceptors
- 1
- Rotatable bonds
- 5
- Heavy atoms
- 18
- Formal charge
- 0
- Complexity
- 214
Physicochemical properties
- Boiling point
- 127 °C · 127 °C(Press: 0.2 Torr)
- Density
- 0.996 · 0.996±0.06 g/cm3(Predicted)
- pka
- 8.88 · 8.88±0.50(Predicted)
- FDA UNII
- 832 I91B · QZH832I91B
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Toxicology
Treatment
Management of acute amphetamine intoxication is largely symptomatic and includes sedation with a barbiturate. If hypertension is marked, the use of a nitrite or rapidly acting alpha receptor blocking agent should be considered. Acidification of the urine increases amphetamine excretion. (L1712)
Health Effects
Using large amounts of these drugs can result in a condition known as amphetamine psychosis -- which can result in auditory, visual and tactile hallucinations, intense paranoia, irrational thoughts and beliefs, delusions, and mental confusion.
Exposure RoutesOral. Readily absorbed from the gastro-intestinal tract and buccal mucosa. It Is resistant to metabolism by monoamine oxidase.
Toxicity Summary
Although the mechanism of action of the sympathomimetic appetite suppressants in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Amphetamine and related sympathomimetic medications (such as benzphetamine) are thought to stimulate the release of norepinephrine and/or dopamine from storage sites in nerve terminals in the lateral hypothalamic feeding center, thereby producing a decrease in appetite. This release is mediated by the binding of benzphetamine to centrally located adrenergic receptors.
Signs and SymptomsAcute overdosage may result in restlessness, tremor, tachypnea, confusion, assaultiveness, and panic states.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Toxicity DataLD50: 160 mg/kg (Oral, Rat) (A308)
Chemistry & industry
Pharmacology
Metabolism/MetabolitesHepatic. Benzphetamine's metabolites include amphetamine and methamphetamine.
Half Life: 16 to 31 hours
Uses & manufacturing
UsesFor the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…